Valuation Charles River Laboratories International, Inc. CBOE

Stocks

Market Closed - CBOE 03:59:50 14/10/2026 HKT			5-day change	1st Jan Change
299.04 ^USD	-1.07%		-2.82%	+51.39%

07:08pm	JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310	MT
10-13	Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	14,275	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	42.42%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	16,366	15,983	15,590
Change	-	-36.28%	7.39%	-20.91%	3.29%	37%	-2.35%	-2.46%
P/E	49.4x	23.1x	25.9x	931x	-70x	72.3x	31.6x	27.9x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	4.62x	4.06x	3.6x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	2.1x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	3.64x	3.55x	3.35x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	4.18x	3.98x	3.66x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	16x	14.4x	13.1x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	19.9x	17.3x	15.1x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	54.4x	31.1x	30.9x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	1.84%	3.21%	3.24%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	4.137	9.458	10.7
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,917	4,018	4,257
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,021	1,109	1,193
EBIT ¹	742.1	834	838.8	805.9	793.9	822.1	921.8	1,030
Net income ¹	391	486.2	474.6	10.3	-144.3	191	437.1	488.2
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,091	1,708	1,315
Reference price ²	375.34	218.92	238.84	186.16	203.66	299.02	299.02	299.02
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	16/2/22	22/2/23	14/2/24	19/2/25	18/2/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
WUXI APPTEC CO., LTD.	20.44x	7.28x	14.62x	1.45%	70.44B
ARGENX SE	27.08x	7.4x	23.22x	0.05%	50.31B
LONZA GROUP AG	33.03x	5.94x	17.79x	0.98%	47.51B
IQVIA HOLDINGS INC.	33.58x	3.26x	14.07x	-.--%	42.91B
REVOLUTION MEDICINES, INC.	-19.54x	197.56x	-20.76x	-.--%	40.39B
BEONE MEDICINES AG	46.24x	5.25x	28.83x	-.--%	39.69B
CELLTRION, INC.	26.84x	7.63x	19.74x	0.4%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	30.94x	6.59x	17.1x	-.--%	26.8B
BIONTECH SE	-13.49x	4.97x	-6x	-.--%	22.36B
Average	20.57x	27.32x	12.07x	0.32%	41.22B
Weighted average by Cap.	22.12x	27.00x	13.15x	0.44%